Biome Australia And 2 Other Promising ASX Penny Stocks To Watch

In This Article:

Over the last 7 days, the Australian market has remained flat, although it is up 22% over the past year with earnings expected to grow by 12% per annum in the coming years. Investing in penny stocks—often smaller or newer companies—can still open doors to growth opportunities when they demonstrate strong financial health. Despite being a somewhat outdated term, penny stocks continue to represent an underappreciated chance for growth at lower price points, and this article will explore several that could pair balance sheet strength with long-term potential.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

LaserBond (ASX:LBL)

A$0.57

A$65.06M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.795

A$128.44M

★★★★☆☆

MaxiPARTS (ASX:MXI)

A$1.825

A$104.82M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.50

A$310.07M

★★★★★☆

Helloworld Travel (ASX:HLO)

A$1.85

A$300.41M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.70

A$842.94M

★★★★★☆

West African Resources (ASX:WAF)

A$1.715

A$1.95B

★★★★★★

Atlas Pearls (ASX:ATP)

A$0.135

A$56.64M

★★★★★★

GTN (ASX:GTN)

A$0.47

A$92.11M

★★★★★★

Joyce (ASX:JYC)

A$3.90

A$115.92M

★★★★★★

Click here to see the full list of 1,027 stocks from our ASX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Biome Australia

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Biome Australia Limited develops, commercializes, and markets various live biotherapeutics and complementary medicines in Australia and internationally, with a market cap of A$150.10 million.

Operations: The company's revenue is derived from its segment focused on innovative evidence-based products linking the gut and human health, totaling A$13.01 million.

Market Cap: A$150.1M

Biome Australia has demonstrated significant sales growth, with a 55% increase in first-quarter revenue for fiscal year 2025 compared to the same period last year, reaching A$4.25 million. Despite being unprofitable, it has reduced losses over five years and maintains more cash than debt. The company's short-term assets comfortably cover both its short and long-term liabilities. However, shareholders experienced dilution with an 8.3% increase in shares outstanding over the past year. While trading below estimated fair value, its high volatility presents potential risks for investors seeking stability in penny stock investments.

ASX:BIO Financial Position Analysis as at Oct 2024
ASX:BIO Financial Position Analysis as at Oct 2024

Frontier Digital Ventures

Simply Wall St Financial Health Rating: ★★★★★☆